Patient characteristics
| Patient characteristics and response to SGN-35 | |
| Median age, y | 35 |
| Male sex, n = 5 | 22/45 (49%) |
| Stage III/IV at first diagnosis, n = 5 | 15/45 (33%) |
| Previous treatment and characterization of chemotherapy sensitivity | |
| Primary refractory disease/early relapse, n (%) | 28/45 (62%) |
| Median number of previous cancer regimens, n (range) | 4 (2-12) |
| Median years between first diagnosis and SGN-35 treatment, n (range) | 4 (0-15) |
| Previous SCT (auto and/or allo SCT), n (%) | 39/45 (87%) |
| Refractory prior to SGN-35, n (%) | 29/45 (64%) |
| Disease status at initiation of SGN-35 | |
| Stage III/IV, n (%) | 33/45 (73%) |
| B-symptoms, n (%) | 20/45 (44%) |
| Extranodal manifestation, n (%) | 33/45 (73%) |
| Large mediastinal tumor, n (%) | 2/45 (4%) |
| ≥ 3 lymph node regions, n (%) | 30/44 (68%) |
| Lactate dehydrogenase > 240 U/L, n (%) | 14/37 (38%) |
| ECOG status ≤ 1, n (%) | 37/45 (82%) |
| Median number of SGN-35 courses, n (range) | 7 (1-12) |
| Best response to SGN-35, n (%) | |
| CR | 10/45 (22%) |
| PR | 17/45 (38%) |
| SD | 13/45 (29%) |
| PD | 5/45 (11%) |
| Patient characteristics and response to SGN-35 | |
| Median age, y | 35 |
| Male sex, n = 5 | 22/45 (49%) |
| Stage III/IV at first diagnosis, n = 5 | 15/45 (33%) |
| Previous treatment and characterization of chemotherapy sensitivity | |
| Primary refractory disease/early relapse, n (%) | 28/45 (62%) |
| Median number of previous cancer regimens, n (range) | 4 (2-12) |
| Median years between first diagnosis and SGN-35 treatment, n (range) | 4 (0-15) |
| Previous SCT (auto and/or allo SCT), n (%) | 39/45 (87%) |
| Refractory prior to SGN-35, n (%) | 29/45 (64%) |
| Disease status at initiation of SGN-35 | |
| Stage III/IV, n (%) | 33/45 (73%) |
| B-symptoms, n (%) | 20/45 (44%) |
| Extranodal manifestation, n (%) | 33/45 (73%) |
| Large mediastinal tumor, n (%) | 2/45 (4%) |
| ≥ 3 lymph node regions, n (%) | 30/44 (68%) |
| Lactate dehydrogenase > 240 U/L, n (%) | 14/37 (38%) |
| ECOG status ≤ 1, n (%) | 37/45 (82%) |
| Median number of SGN-35 courses, n (range) | 7 (1-12) |
| Best response to SGN-35, n (%) | |
| CR | 10/45 (22%) |
| PR | 17/45 (38%) |
| SD | 13/45 (29%) |
| PD | 5/45 (11%) |
CR indicates complete remission; PR, partial remission; SD, stable disease; and PD, progressive disease.